
Product Data Sheet

Product Name: Temarotene (Ro 15-0778)

Cat. No.: GC31845

Chemical Properties

Cas. No. 75078-91-0

SMILES C/C(C1=CC2=C(C(C)(C)CCC2(C)C)C=C1)=C\C3=CC=CC=C3Formula C₂₃H₂₈ M.Wt 304.47

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Temarotene is an orally administered, particular arotinoid.

Modulation of ornithine decarboxylase (ODC) gene expression by retinoids is analyzed in human keratinocyte cultures maintained in serum-free medium containing 0.15 mM Ca²⁺. Cells are incubated with all-trans-retinoic acid, 13-cis-retinoic acid or arotinoid Ro15-0778 (0.1 nM to 10 μM), total RNA is isolated, and mRNA transcripts for ODC are analyzed by Northern and slot blot hybridizations with a human ODC cDNA. Treatment of cells for 24 h results in a dose-dependent decrease in ODC mRNA levels, with an estimated IC₅₀ of approximately 10 nM for all-trans- and 13-cis-retinoic acid, while Ro15-0778 is somewhat less effective (IC₅₀ approximately 0.1-0.5 μM). The suppression of ODC mRNA levels by retinoids is detectable at approximately 3 h of incubation, with essentially a maximal inhibition at 12 h. Reduced ODC mRNA levels noted after 24 h of incubation with 0.5 μM all-trans-retinoic acid are accompanied by a reduction in ODC enzyme activity[1].

The aim of this preliminary report is to measure plasma and skin concentrations of Ro 15-0778 and its phenolic metabolite Ro 14-6113 in hairless rats receiving orally 10

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

mg/kg of Tamarotene once daily during 10 days. Blood (2-3 mL) and skin (200-300 mg) samples are taken at different time points between 0.5 and 240 h after the last dose. A highly sensitive HPLC method is used for simultaneous determination of the two compounds with a quantification limit of 2 ng/mL in plasma and 10 ng/g in total skin (epidermis and dermis). After 10 h, plasma concentrations of Ro 14-6113 are 5-13 times higher than for Ro 15-0778. Ro 14-6113 concentrations in the skin are 4-10 times higher than for Ro 15-0778 within the initial 48 h. The concentrations of both compounds in the skin are higher than concentrations in plasma[1].

[1]. Olsen DR, et al. Suppression of ornithine decarboxylase gene expression by retinoids in cultured human keratinocytes. *J Invest Dermatol.* 1990 Jan;94(1):33-6. [2]. Fenina N, et al. Concentration of Tamarotene (Ro 15-0778) and its metabolite Ro 14-6113 in plasma and skin of hairless rat. *Skin Pharmacol.* 1993;6(1):61-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA